What's Behind GW Pharmaceuticals' 6.4% Gain in October?

Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from S&P Global Market Intelligence. Investors were pleased to see the company complete a rolling submission of Epidiolex's new drug application, setting the stage for a potential blockbuster drug launch.

GW Pharmaceuticals is developing Epidiolex, a proprietary cannabinoid, as a treatment for two rare forms of epilepsy. Data from clinical trials supporting the recently completed application suggests it could be a major improvement over available treatments that are often ineffective and poorly tolerated.

Image source: Getty Images.

Source: Fool.com